ADVISORY-Ignore incorrect advisory alert on Beyond Cancer coding error

Reuters
04 Dec 2024
ADVISORY-Ignore incorrect advisory alert on Beyond Cancer coding error

An incorrect advisory alert saying Beyond Cancer's clinical trial approval was wrongly tagged to Beyond Air XAIR.O has been withdrawn.

Beyond Cancer is a unit of biopharma company Beyond Air, and the original alert from Beyond Cancer's press release was correctly coded.

For the correctly coded alert on Beyond Cancer's clinical trial approval, click nFWN3N415S

STORY_NUMBER: nFWN3N410N

STORY_DATE: 03/12/2024

STORY_TIME: 09:14:12 PM GMT

((bangalore.newsroom@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10